Optogenetic Treatment Era in Retinal Diseases and Night Blindness
Developed against the risk of blindness and receiving FDA approval, the light gene therapy will begin to be applied for patients next year.
World-renowned ophthalmology expert Prof. Dr. SriniVas Sadda shared the details of optogenetic treatment, which is groundbreaking in the treatment of retinal diseases and night blindness.
Prof. Dr. SriniVas Sadda Visited Turkey
Prof. Dr. SriniVas Sadda, President of the Doheny Eye Institute at the University of California School of Medicine, came to Turkey to share innovations in the fields of retinal diseases and gene therapy.
The Purpose of Optogenetics and Light Gene Therapy
In cases where light-sensitive cells are lost, gene transfer is performed to the remaining cells, enabling cells that normally cannot perceive light to respond, aiming to regain vision.
Approval Process in Night Blindness Treatment
Clinical research has been completed for retinitis pigmentosa, commonly known as night blindness, and the treatment has been approved by the FDA, EMA, and the Japanese Ministry of Health.
Application Method and Duration of Persistence
The treatment is administered via an intraocular injection in an operating room setting, and studies have determined that patients' visual improvement is maintained for three years.